<DOC>
	<DOCNO>NCT02396043</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability treatment T-lymphoblastic lymphoma ( T-LBL ) accord modify BFM-95 regimen acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Modified BFM-95 Regimen First-Line Chemotherapy Adults With T- Lymphoblastic Lymphoma</brief_title>
	<detailed_description>All patient receive modified BFM regimen derive NHL-BFM-95 . Th e diff erences follow : ( 1 ) course high-dose methotrexate therapy ( HD-MTX ) , citrovorum folinate ( CF ) use rescue 36 h administration HD-MTX ; ( 2 ) cranial prophylactic radiotherapy omit , patient receive regular intrathecal chemotherapy four additional HD-MTX treatment maintenance therapy . ( 3 ) Pirarubicin use instead daunorubicin ( 4 ) Pegaspargase use instead L- asparaginase patient</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>newly diagnosedTLBL age:1865years Ann Arbor stage IEto stage IVE lease one measurable lesion receive chemotherapy radiotherapy Adequate renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>